Panmure Gordon Lowers EKF Diagnostics (OTCMKTS:EKDHF) to Hold

Panmure Gordon downgraded shares of EKF Diagnostics (OTCMKTS:EKDHF) from a buy rating to a hold rating in a report published on Tuesday, The Fly reports.

EKDHF opened at $0.70 on Tuesday. EKF Diagnostics has a 52 week low of $0.68 and a 52 week high of $0.70.

About EKF Diagnostics

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.

See Also: What is the definition of market timing?

The Fly

Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit